{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T15:08:21Z","timestamp":1769612901159,"version":"3.49.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T00:00:00Z","timestamp":1571356800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T00:00:00Z","timestamp":1571356800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"John Pickering and Partners Charitable Trust","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The Mesothelioma and Radical Surgery Trial (MARS 2) aims to evaluate a surgical procedure by comparing chemotherapy and surgery against chemotherapy alone. The pilot study for MARS 2 evaluated the viability of recruitment. Challenges have been reported in conducting clinical research into thoracic surgical treatments and evidence is required to improve our understanding of patient experiences of trial procedures, trial treatments and the factors that influence participation.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This longitudinal qualitative study was nested within the MARS 2 pilot. Semi-structured telephone interviews were conducted with 15 participants in the MARS 2 trial. Interviews were conducted post-randomisation, post-surgery (surgery arm) and at 6 and 12\u2009months. Altogether, 41 interviews were carried out. The data were analysed using framework techniques.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Challenges were identified regarding the volume and complexity of information given to participants, and their understanding of clinical equipoise and randomisation. Factors influencing participation included having an opportunity to undergo surgery, a self-assessment of their ability to cope with trial treatments, maintaining a positive approach and altruism. Obstacles included the logistics of traveling for treatment in an unfamiliar setting. Negative consequences of trial participation included increased uncertainty amplified by multiple care providers and unclear transition arrangements after the trial.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Participants\u2019 descriptions provided insights that have implications for care for mesothelioma trial patients. The need for healthcare staff to be alert to the potential for misunderstanding, particularly when presenting treatment options, was identified. Patients perceived and derived benefits from taking part in the trial but experienced some negative consequences. These should be anticipated and managed proactively.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02040272\">NCT02040272<\/jats:ext-link>. Registered on 20 January 2014.\u00a0<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-019-3692-x","type":"journal-article","created":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T12:04:10Z","timestamp":1571400250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Patient experiences of participation in a radical thoracic surgical trial: findings from the Mesothelioma and Radical Surgery Trial 2 (MARS 2)"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8356-4199","authenticated-orcid":false,"given":"Clare","family":"Warnock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Lord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethany","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Tod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,18]]},"reference":[{"key":"3692_CR1","unstructured":"Cancer Research UK Mesothelioma Incidence Statistics. \n                    https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/mesothelioma\/incidence#heading-Seven\n                    \n                  . Accessed 22 Oct 2018."},{"issue":"9","key":"3692_CR2","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1080\/14656566.2016.1176145","volume":"17","author":"C Maggioni","year":"2016","unstructured":"Maggioni C, Barletta G, Rijavec E, Biello F, Gualco E, Grossi F. Advances in treatment of mesothelioma. Expert Opin Pharmacother. 2016;17(9):1197\u2013205.","journal-title":"Expert Opin Pharmacother"},{"key":"3692_CR3","volume-title":"National Mesothelioma Audit Report (for the audit period 2014-16)","author":"Royal College of Physicians","year":"2018","unstructured":"Royal College of Physicians. National Mesothelioma Audit Report (for the audit period 2014-16). 2018. \n                    https:\/\/www.rcplondon.ac.uk\/projects\/outputs\/national-mesothelioma-audit-report-2018-audit-period-2014-16\n                    \n                  . Accessed Oct 2018."},{"key":"3692_CR4","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1111\/crj.12938","volume":"12","author":"AC Bibby","year":"2018","unstructured":"Bibby AC, Maskell NA. Current treatments and trials in malignant pleural mesothelioma. Clin Respir J. 2018;12:2161\u20139.","journal-title":"Clin Respir J"},{"key":"3692_CR5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1258\/jrsm.2011.110307","volume":"105","author":"T Treasure","year":"2012","unstructured":"Treasure T, Morton D. GRIST: Growing Recruitment in Interventional and Surgical Trials. J R Soc Med. 2012;105:140\u20131.","journal-title":"J R Soc Med"},{"key":"3692_CR6","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.lungcan.2013.11.026","volume":"83","author":"C Cao","year":"2014","unstructured":"Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014;83:240\u20135.","journal-title":"Lung Cancer"},{"key":"3692_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bulcan.2015.10.006","volume":"103:1","author":"S Evrard","year":"2016","unstructured":"Evrard S. Rethinking clinical research in surgical oncology. From comic opera to quality control. Bull Cancer. 2016;103:1:87\u201395.","journal-title":"Bull Cancer"},{"key":"3692_CR8","unstructured":"Importance, Obstacles & Stories of Mesothelioma Clinical Trials. \n                    https:\/\/www.asbestos.com\/treatment\/clinical-trials\/participant-stories\/\n                    \n                  . Accessed 17 Sept 2019."},{"key":"3692_CR9","volume-title":"The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies","author":"M Joseph","year":"2016","unstructured":"Joseph M, Unger JM, Cook E, Tai E, Bleyer A. The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. 2016 \n                    https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5495113\/\n                    \n                  . Accessed Nov 2018."},{"key":"3692_CR10","volume-title":"Qualitative Research Practice","author":"J Ritchie","year":"2013","unstructured":"Ritchie J, Lewis J, McNaughton Nicholls C, Ormston R. Qualitative Research Practice. London: Sage; 2013."},{"key":"3692_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13063-016-1391-4","volume":"17","author":"JL Donovan","year":"2016","unstructured":"Donovan JL, Rooshenas L, Jepson M, Elliot D, Wade J, Avery K, et al. Optimising recruitment and informed consent in randomised controlled trials: the development and implementation of the Quintet Recruitment Intervention (QRI). Trials. 2016;17:283.","journal-title":"Trials"},{"key":"3692_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/jme.2010.035485","volume":"37","author":"C Beherndt","year":"2011","unstructured":"Beherndt C, Golz T, Roesler C, Bertz H, Wunsch A. What do our patients understand about their trial participation? Assessing patients\u2019 understanding of their informed consent consultation about randomised clinical trials. J Med Ethics. 2011;37:74\u201380.","journal-title":"J Med Ethics"},{"key":"3692_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/ecc.12184","volume":"24","author":"T Godskesen","year":"2015","unstructured":"Godskesen T, Hansson MG, Nygren P, Nordin K, Kihlbom U. Hope for a cure and altruism are the main motives behind participation in phase 3 clinical trials. Eur J Cancer Care. 2015;24:133\u201341.","journal-title":"Eur J Cancer Care"},{"key":"3692_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00520-009-0787-z","volume":"19","author":"AC Wooten","year":"2011","unstructured":"Wooten AC, Abbott JM, Siddons HM, Rosenthal MA, Costello AJ. A qualitative assessment of the experience of participating in a cancer-related clinical trial. Support Care Cancer. 2011;19:49\u201355.","journal-title":"Support Care Cancer"},{"key":"3692_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1200\/JCO.2013.51.7359","volume":"32","author":"EH Wagner","year":"2014","unstructured":"Wagner EH, Ludman EJ, Aiello Bowles EJ, Penfold R, Reid RJ, Rutter CM, et al. Nurse navigators in early cancer care: a randomized clinical trial. J Clin Oncol. 2014;32:12\u20138.","journal-title":"J Clin Oncol"},{"key":"3692_CR16","unstructured":"Macmillan cancer care UK, Recovery package. \n                    https:\/\/www.macmillan.org.uk\/about-us\/health-professionals\/programmes-and-services\/recovery-package\n                    \n                  . Accessed 23 Aug 2019."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3692-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-019-3692-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3692-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T23:12:49Z","timestamp":1602889969000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-3692-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,18]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3692"],"URL":"https:\/\/doi.org\/10.1186\/s13063-019-3692-x","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,18]]},"assertion":[{"value":"21 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Approval was obtained from NHS Ethics Committee London \u2013 Camberwell St Giles (reference 13\/10\/1481). This included the QSS. Informed consent was also obtained from each participant prior to involvement in the QSS.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Participants consented to their anonymised quotes being published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"598"}}